American College of Cardiology

GALACTIC-HF shows that investigational agent omecamtiv mecarbil works best in heart failure patients with markedly reduced ejection fraction

American College of Cardiology

Dapagliflozin does not improve outcomes in hospitalized patients with COVID-19, but shows safety in patients with cardiometabolic risk factors 

American College of Cardiology

Pooled data from phase 3 trials shows that investigational SGLT1/2 inhibitor sotagliflozin significantly reduces risk of CV events in T2DM patients with HF or mild renal impairment

American College of Cardiology

Sacubitril/valsartan comes up short in high-risk HFrEF patients post-MI

American College of Cardiology

CONNECT-HF Highlights persisting gaps in heart failure care

The Lancet

Aspirin vs Clopidogrel for Chronic Maintenance Monotherapy After PCI

New CMHC Masterclass LIVE

Roadblocks & Reflections: Addressing the Disproportionate Burden & Disparities with COVID-19.

Hear this multidisciplinary panel, chaired by Dr. Keith C. Ferdinand, discuss COVID-19 disparities, the ongoing issue of vaccine hesitancy, as well as future directions and perspectives.